2024/ABM/05/KPO/KPOD.07.07-IW.07-0249/24

The company NanoSanguis is pursuing a venture into Dextran conjugates for targeted anticancer therapy subsidized by the Medical Research Agency under the NTP, Component D: Efficiency, accessibility and quality of the health care system, Investment D3.1.1 Comprehensive development of research in medical and health sciences.

The goal of the project is to develop innovative combinations of cytostatic drugs with a dextran carrier and a targeting agent with potentially improved efficacy and a more favorable safety profile for patients.

The project plans to develop pathways for the synthesis of conjugates, study drug release kinetics, conduct in vitro studies, perform comparative cytotoxicity studies, and conduct preliminary studies in mice.

The venture’s target group is oncology patients. The launch of targeted cancer therapy could revolutionize cancer treatment, improving patients’ quality of life.

The intended effect of the project is to improve the resulting therapeutic effectiveness. This will be achieved in two ways:

• By increasing patient safety through the use of a lower or the same dose of the drug (depending on the leading therapeutic need and/or

• By increasing the dose of the drug with the same level of patient safety

Value of the project: PLN 2,523,452.23

Value of EU funding: PLN 2,018,761.77